soft tissue sarcoma
Oncology · 2012–2013
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pazopanib Initial and continuing treatment of advanced (unresectable and/or metastatic) soft tissue sarcoma (STS) in patients who have received prior chemotherapy… | Jul 2013 | Recommended with restriction | no section in document |
| pazopanib Initial and continuing treatment of advanced (unresectable and/or metastatic) soft tissue sarcoma in patients who have received prior anthracycline treatment… | Nov 2012 | Recommended with restriction | no section in document |
What the PBS pays
$9M in government benefit over 2024–25, across 2,655 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pazopanib | $9.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| trabectedinTrabectedin for the treatment of advanced soft tissue sarcoma | TA185 | recommended | 2010-02 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| epirubicinEPIRUBICIN ACCORD epirubicin hydrochloride 10mg/5mL concentrated injec | 1992 | 5 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.